Shire (SHPG) Downgraded by JPMorgan Chase & Co. to Neutral

JPMorgan Chase & Co. cut shares of Shire (NASDAQ:SHPG) from an overweight rating to a neutral rating in a research note issued to investors on Monday morning, The Fly reports.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a buy rating in a research note on Tuesday, December 5th. Royal Bank of Canada reissued a buy rating on shares of Shire in a research note on Thursday, November 16th. Liberum Capital raised Shire from a hold rating to a buy rating in a research note on Tuesday, November 14th. FBR & Co reissued a buy rating and issued a $201.00 target price on shares of Shire in a research note on Monday, October 30th. Finally, Cowen set a $225.00 target price on Shire and gave the stock a buy rating in a research note on Sunday, October 29th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $209.23.

Shares of Shire (NASDAQ SHPG) opened at $134.06 on Monday. Shire has a 12 month low of $123.73 and a 12 month high of $192.15. The company has a market capitalization of $40,900.00, a price-to-earnings ratio of 6.12, a PEG ratio of 0.75 and a beta of 1.41. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.

Shire (NASDAQ:SHPG) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, topping analysts’ consensus estimates of $3.86 by $0.12. Shire had a return on equity of 14.75% and a net margin of 28.17%. The firm had revenue of $4.14 billion for the quarter. During the same period in the prior year, the company posted $3.37 earnings per share. The company’s revenue was up 8.9% on a year-over-year basis. equities research analysts anticipate that Shire will post 15.27 EPS for the current year.

The firm also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be given a dividend of $0.8937 per share. The ex-dividend date of this dividend is Thursday, March 8th. This is a boost from Shire’s previous semiannual dividend of $0.15. This represents a dividend yield of 1.33%. Shire’s dividend payout ratio (DPR) is 4.20%.

Several institutional investors have recently added to or reduced their stakes in the stock. Commerzbank Aktiengesellschaft FI boosted its position in Shire by 22.1% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 375 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Shire by 6.2% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock worth $1,073,000 after purchasing an additional 381 shares during the last quarter. Pitcairn Co. boosted its position in Shire by 26.5% in the third quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock worth $293,000 after purchasing an additional 401 shares during the last quarter. ETRADE Capital Management LLC boosted its position in Shire by 6.9% in the fourth quarter. ETRADE Capital Management LLC now owns 7,212 shares of the biopharmaceutical company’s stock worth $1,119,000 after purchasing an additional 466 shares during the last quarter. Finally, Thompson Investment Management Inc. boosted its position in Shire by 5.2% in the third quarter. Thompson Investment Management Inc. now owns 9,390 shares of the biopharmaceutical company’s stock worth $1,438,000 after purchasing an additional 468 shares during the last quarter. 20.92% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Shire (SHPG) Downgraded by JPMorgan Chase & Co. to Neutral” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://stocknewstimes.com/2018/02/20/shire-shpg-downgraded-by-jpmorgan-chase-co-to-neutral.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

The Fly

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply